309 related articles for article (PubMed ID: 31727675)
21. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
24. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
25. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
26. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
André T; Chibaudel B
Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Denda T; Sakai D; Hamaguchi T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Sunaga Y; Ziti-Ljajic S; Brillac C; Yoshino T
Cancer Sci; 2019 Mar; 110(3):1032-1043. PubMed ID: 30657223
[TBL] [Abstract][Full Text] [Related]
28. [The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.].
Masi G; Borelli B
Recenti Prog Med; 2018 Nov; 109(11):15e-19e. PubMed ID: 30565582
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Hayashi H; Arao T; Matsumoto K; Kimura H; Togashi Y; Hirashima Y; Horita Y; Iwasa S; Okita NT; Honma Y; Takashima A; Kato K; Hamaguchi T; Shimada Y; Nakagawa K; Nishio K; Yamada Y
Oncotarget; 2014 May; 5(9):2588-95. PubMed ID: 24809949
[TBL] [Abstract][Full Text] [Related]
30. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Di Desidero T; Canu B; Schirripa M; Frumento P; Di Paolo A; Danesi R; Falcone A; Bocci G
Br J Cancer; 2011 Apr; 104(8):1262-9. PubMed ID: 21407216
[TBL] [Abstract][Full Text] [Related]
32. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
33. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Pentheroudakis G; Kotoula V; Koliou GA; Karavasilis V; Samantas E; Aravantinos G; Kalogeropoulou L; Souglakos I; Kentepozidis N; Koumakis G; Sgouros J; Zarkavelis G; Efstratiou I; Laschos K; Petraki C; Tikas I; Poulios C; Voutsina A; Goudopoulou A; Bafaloukos D; Vrettou E; Kalogera-Fountzila A; Pectasides D; Fountzilas G
Clin Colorectal Cancer; 2018 Dec; 17(4):e631-e637. PubMed ID: 29980490
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
36. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
[TBL] [Abstract][Full Text] [Related]
38. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
39. Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Piringer G; Thaler J; Anchisi S; Geffriaud-Ricouard C; Gueldner M; Scholten F; Derigs HG; Bohanes P; Grünberger B; Schwarz L; von Moos R; Hofheinz RD
J Geriatr Oncol; 2023 Nov; 14(8):101638. PubMed ID: 37776611
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
